Ab213521

Manufactured by Cell Signaling Technology

Sourced in United States

Ab213521 is a primary antibody product developed by Cell Signaling Technology. It is used in various laboratory applications to detect and study specific target proteins.

Automatically generated - may contain errors

Lab products found in correlation

Ab56416, by Cell Signaling Technology (2 mentions) Ab124715, by Cell Signaling Technology (2 mentions) Ab181602, by Cell Signaling Technology (2 mentions) Sp600125, by Selleck Chemicals (1 mentions) Ab15580, by Cell Signaling Technology (1 mentions) Piperlongumine, by Selleck Chemicals (1 mentions) Ab207612, by Cell Signaling Technology (1 mentions)

2 protocols using ab213521

BMP4, Noggin, and Autophagy Regulation

Check if the same lab product or an alternative is used in the 5 most similar protocols

Recombinant human BMP4 (120-05) or Noggin (120-10C) were purchased from PeproTech (Rocky Hill, NJ). 3-Methyladenine (3-MA) (S2767) and JNK inhibitor SP600125 (S1460) were purchased from Selleckchem (Houston, TX, USA). Rapamycin (Rapa, V900930) was purchased from Sigma Chemical Co. (St. Louis, MO, USA). Reagents were reconstituted and stored according to the manufacturer’s description. Antibodies against BMP4 (ab124715), LC3 (#4108), SQSTM1/p62 (ab56416), Beclin1 (BECN1, ab207612), JNK1 (ab213521), phospho-JNK (Thr183/Tyr185) (#4668), Bcl-2 (#4223), phospho-Bcl2 (Ser70) (#2827), LC3B (ab51520), Ki-67 (ab15580) and GAPDH (ab181602) were purchased from Cell Signaling Technology (Beverly, MA, USA) and Abcam (Cambridge, UK).

Deng G., Zeng S., Qu Y., Luo Q., Guo C., Yin L., Han Y., Li Y., Cai C., Fu Y, & Shen H. (2018). BMP4 promotes hepatocellular carcinoma proliferation by autophagy activation through JNK1-mediated Bcl-2 phosphorylation. Journal of Experimental & Clinical Cancer Research : CR, 37, 156.

+ Open protocol

+ Expand

Investigating PI3K/AKT Signaling Modulators

Check if the same lab product or an alternative is used in the 5 most similar protocols

The PI3K/AKT Inhibitor Piperlongumine (S7551) and AKT activator SC79 (S7863) were purchased from Selleck‐chem (Houston, TX, USA). Reagents were reconstituted and stored according to the manufacturer's instructions. Antibodies against MLH1 (ab124715), EGFR (#4108), p‐EGFR (ab56416), Her‐2 (BECN1, ab207612), PI3K (ab213521), AKT (#4668), Bcl‐2 (#4223), Bax (ab51520), active caspase‐3 (ab15580), and GAPDH (ab181602) were purchased from Cell Signaling Technology (Beverly, MA, USA) and Abcam (Cambridge, UK).

Han Y., Peng Y., Fu Y., Cai C., Guo C., Liu S., Li Y., Chen Y., Shen E., Long K., Wang X., Yu J., Shen H, & Zeng S. (2020). MLH1 Deficiency Induces Cetuximab Resistance in Colon Cancer via Her‐2/PI3K/AKT Signaling. Advanced Science, 7(13), 2000112.

+ Open protocol

+ Expand

About PubCompare

Our mission is to provide scientists with the largest repository of trustworthy protocols and intelligent analytical tools, thereby offering them extensive information to design robust protocols aimed at minimizing the risk of failures.

We believe that the most crucial aspect is to grant scientists access to a wide range of reliable sources and new useful tools that surpass human capabilities.

However, we trust in allowing scientists to determine how to construct their own protocols based on this information, as they are the experts in their field.

Ready to get started?

Revolutionizing how scientists
search and build protocols!